| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/29/1994 | EP0559838A4 Ecteinascidins 736 and 722 |
| 06/29/1994 | EP0470183B1 Fibroblast growth factor conjugates |
| 06/29/1994 | CN1088583A Phospholipi derivatives containing higher elements of the Vth main group |
| 06/29/1994 | CN1088582A Quaternary basic amides, method of preparing them and pharmaceutical compositions in which they are present |
| 06/29/1994 | CN1088577A Novel multi-drug resistance modifier |
| 06/29/1994 | CN1088435A Anti-arrhythmic, analgesically acting phthalzinone derivatives that break through multi-drug-resistance |
| 06/29/1994 | CA2094753A1 5,6,7,9-tetrahydro-1,2,3,-trimethoxy-9-oxobenzo[.alpha.]heptalene derivative |
| 06/28/1994 | US5324859 Deuterated benzaldehydes |
| 06/28/1994 | US5324840 Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects |
| 06/28/1994 | US5324740 For treating fungal diseases or estrogen-dependent disorders |
| 06/28/1994 | US5324731 Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated |
| 06/28/1994 | US5324720 Methods of achieving antitumor activity using 16-membered-macrolide-type compounds |
| 06/28/1994 | US5324655 Human Y-interferon signal peptide-tumor necrosis factor(TNF) gene fusions |
| 06/28/1994 | CA1330436C Water soluble, antineoplastic derivatives of taxol |
| 06/28/1994 | CA1330422C Reduction of neurotoxic effects of cytotoxic agents |
| 06/26/1994 | CA2111931A1 .alpha.-aminoketone derivatives |
| 06/23/1994 | WO1994013824A1 Retroviral vectors for the treatment of tumors, and cell lines containing them |
| 06/23/1994 | WO1994013817A1 Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| 06/23/1994 | WO1994013808A2 LYMPHOTOXIN-β, LYMPHOTOXIN-β COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF |
| 06/23/1994 | WO1994013791A1 Regulatable nucleic acid therapeutic and methods of use thereof |
| 06/23/1994 | WO1994013695A1 Dolostatin analog |
| 06/23/1994 | WO1994013687A1 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| 06/23/1994 | WO1994013684A1 Novel substance dolastatin c and pharmaceutical use thereof |
| 06/23/1994 | WO1994013674A1 Antitumour agents |
| 06/23/1994 | WO1994013668A1 Novel bicyclic pyrimidine compounds, method for preparing same and pharmaceutical compositions containing said compounds |
| 06/23/1994 | WO1994013655A1 7-HALO- AND 7β,8β-METHANO-TAXOLS, ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| 06/23/1994 | WO1994013654A1 Novel taxoids, preparation thereof and pharmaceutical compositions containing same |
| 06/23/1994 | WO1994013645A1 Novel selective aromatase inhibiting compounds |
| 06/23/1994 | WO1994013639A1 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists |
| 06/23/1994 | WO1994013324A1 Lipid prodrugs for oral administration |
| 06/23/1994 | WO1994008578A3 Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies |
| 06/23/1994 | CA2151953A1 "dolostatin analog" (novel peptides, the preparation and use thereof) |
| 06/23/1994 | CA2150951A1 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists |
| 06/23/1994 | CA2150904A1 Novel selective aromatase inhibiting compounds |
| 06/23/1994 | CA2150711A1 Antitumour agents |
| 06/23/1994 | CA2150536A1 Retroviral vectors for the treatment of tumors, and cell lines containing them |
| 06/23/1994 | CA2150249A1 Lymphotoxin-.beta., lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof |
| 06/23/1994 | CA2150033A1 Transdermal administration system containing acetylsalicylic acid for antithrombotic therapy and the prevention of cancer |
| 06/23/1994 | CA2149754A1 Lipid prodrugs for oral administration |
| 06/23/1994 | CA2149021A1 7-halo- and 7beta,8beta-methano-taxols, antineoplastic use and pharmaceutical compositions containing them |
| 06/23/1994 | CA2117462A1 New pyrimidine bicyclic compounds; process for preparing the same; pharmaceutical compositions containing them |
| 06/23/1994 | CA2110939A1 An innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements |
| 06/23/1994 | CA2110852A1 Monoclonal antibodies that define a unique antigen of human b cell receptor complex and methods of using same for diagnosis and treatment |
| 06/22/1994 | EP0603160A2 Compositions for in-situ active compound assembly |
| 06/22/1994 | EP0602878A1 Diarylsulfonylureas and their use as antitumor agents |
| 06/22/1994 | EP0602851A1 Quinazoline derivatives |
| 06/22/1994 | EP0602686A2 Lectin concentrates of mistletoe extracts and corresponding standardized, stabilized mistletoe lectin preparations, process for their production as well as medicines containing them and their use |
| 06/22/1994 | EP0602597A2 Process for preparation of indolopyrrolocarbazole derivatives |
| 06/22/1994 | EP0602478A1 Novel process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives |
| 06/22/1994 | EP0602454A1 N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines |
| 06/22/1994 | EP0602144A1 Dna sequences encoding gelonin polypeptide |
| 06/22/1994 | EP0602123A1 Steroid sulphatase inhibitors |
| 06/22/1994 | EP0602118A1 $i(IN VIVO) GENE TRANSFER USING IMPLANTED RETROVIRAL PRODUCER CELLS |
| 06/22/1994 | EP0205586B1 Composition comprising udpg and other anti-tumor drugs for treatment of tumors |
| 06/22/1994 | EP0176588B1 Platelet related growth regulator |
| 06/22/1994 | CN1088216A Modified platelet factor-4 |
| 06/22/1994 | CN1088210A Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them |
| 06/22/1994 | CN1088209A Heterocyclic compounds |
| 06/22/1994 | CN1088095A Anti-cancer therapeutic compositions for prophylaxis or for treatment of cancer |
| 06/22/1994 | CA2111902A1 Antitumor compositions and methods of treatment |
| 06/22/1994 | CA2111875A1 P-[bis(2-chloroethyl)amino]phenylalanine derivatives; process for preparing the same and pharmaceutical compositions containing them |
| 06/21/1994 | US5322854 Antibiotic |
| 06/21/1994 | US5322852 Aminooxy piperidines as ornithine decarboxylase inhibitors |
| 06/21/1994 | US5322844 Cardiovascular disorders, antiinflammatory agents, antiallergens |
| 06/21/1994 | US5322678 Alteration of pharmacokinetics of proteins by charge modification |
| 06/21/1994 | CA1330295C Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas |
| 06/16/1994 | DE4334726A1 Jatrophon contg. extracts for tumour treatment - consist of organic solvent extracts from fresh tubers, Batata-de-teiu, from Mandevilla velutina |
| 06/16/1994 | DE4241632A1 New (aza)aromatic or alicyclic carboxylic acid cpds. - used e.g. for treating thrombosis, inflammation, osteoporosis, cardiac infarct or tumour metastasis |
| 06/15/1994 | EP0601859A2 Pharmaceutic composition comprising cancer-related antibodies |
| 06/15/1994 | EP0601573A1 Alpha-phosphonocarboxylate squalene synthetase inhibitors and method |
| 06/15/1994 | EP0601417A2 Physiologically compatible and degradable polymer-based carbohydrate receptor blockers, a method for their preparation and their use |
| 06/15/1994 | EP0601043A1 Hybrid cytokines |
| 06/15/1994 | EP0600880A1 INTERLEUKIN 1$g(b) PROTEASE AND INTERLEUKIN 1$g(b) PROTEASE INHIBITORS |
| 06/15/1994 | EP0441832B1 Composition and treatment with biologically active peptides and certain anions |
| 06/15/1994 | CN1087913A Rapamycin derivatives |
| 06/15/1994 | CN1087912A Rapamycin derivatives |
| 06/15/1994 | CN1087911A Rapamycin derivatives |
| 06/15/1994 | CN1087905A Preparation of derivative of taxane |
| 06/15/1994 | CN1087904A Carboxylic acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them |
| 06/15/1994 | CN1087900A Benzoylguanidine, preparation of same and application as pharmaceutical and pharmaceutical containing same |
| 06/14/1994 | US5321150 Treating susceptible neoplasms in mammals |
| 06/14/1994 | US5321140 Pyridinecarboxaldehyde D-ring intermediates useful for the synthesis of camptothecin and camptothecin analogs |
| 06/14/1994 | US5320956 Ovarian, esophageal and cervical carcinomas |
| 06/14/1994 | US5320947 Immune reactivity to expressed activated oncogenes for diagnosis of malignancy |
| 06/14/1994 | US5320840 Continuous release pharmaceutical compositions |
| 06/12/1994 | CA2111129A1 Physiologically tolerated and physiologically degradable polymer-based carbohydrate receptor blocker, a process for its preparation and its use |
| 06/11/1994 | CA2111035A1 Carboxylic acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them |
| 06/11/1994 | CA2110525A1 Antitumor compositions and methods of treatment |
| 06/11/1994 | CA2110524A1 Antitumor compositions and methods of treatment |
| 06/10/1994 | CA2109771A1 .alpha.-phosphonocarboxylate squalene synthetase inhibitors |
| 06/09/1994 | WO1994012880A2 Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression |
| 06/09/1994 | WO1994012631A1 Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors |
| 06/09/1994 | WO1994012521A1 Cellular genes encoding retinoblastoma-associated proteins |
| 06/09/1994 | WO1994012517A1 Sequence-specific binding polymers for duplex nucleic acids |
| 06/09/1994 | WO1994012484A1 Novel method for preparing taxane derivatives, novel derivatives thus obtained and compositions containing them |
| 06/09/1994 | WO1994012239A1 Method of activating photosensitive agents |
| 06/09/1994 | WO1994012206A1 Treatment of dermatological malignancies with biologically active peptides |
| 06/09/1994 | WO1994012202A1 ACTIVATION OF p53 PROTEIN |
| 06/09/1994 | WO1994012171A1 Injectable taxane derivative based compositions |
| 06/09/1994 | WO1994012169A1 Carboxy-peptidyl derivatives as antidegenerative active agents |